On July 4, Jiangsu Xihong Biopharma Co., Ltd. (Xihong Biopharma) and So Young Technology Co., Ltd. (So Young) signed an exclusive distribution agreement for two products: Injectable Sodium Hyaluronate Complex Solution and the Next-Generation Injectable Poly-L-Lactic Acid Microspheres for Facial Fillers, with a 10-year authorization period.
Through this partnership, both companies will leverage Xihong Biopharma's strong capabilities in product development, technological innovation, and biological research, while utilizing So Young's expertise in internet influence, product operations, and supply chain management. Together, they will create new consumer experiences in the regenerative medicine industry, promote the standardization and quality development of the industry, and achieve a win-win situation through mutual empowerment.
Zhang Xinming, Chairman of Xihong Biopharma, shared his outlook on the collaboration: "In the future, Xihong Biopharma is committed to working with So Young to create a cooperation effect where 1+1>2. By utilizing our strengths, we will efficiently promote the partnership, provide high-quality products and services to regenerative medicine users, and inject continuous vitality into the industry."
(▲Zhang Xinming, Chairman of Xihong Biopharma)
Jin Xing, Chairman and CEO of So Young, commented: "The strategic partnership with Xihong Biopharma not only fills the gap in So Young’s regenerative product offerings but also enriches our portfolio in the regenerative medicine field. It will bring even better products for the health and beauty of the Chinese people. In the future, So Young will leverage its platform advantages to collaborate with Xihong Biopharma and usher in a new era of regenerative products, creating new breakthroughs and setting industry benchmarks."
(▲Jin Xing, Chairman and CEO of So Young)
Looking ahead, with the combined advantages of rapid market growth, technological innovation, and business model innovation, Xihong Biopharma will continue to focus on technological advancements and providing high-quality products. The company aims to fully utilize its comprehensive strengths in technology, production capacity, and production lines, actively interact with industry partners, and promote the deep integration of the ability chain, innovation chain, industry chain, and capital chain. Together, they will co-create a bright future for the regenerative medicine market.
